Login Register Cart 0
Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Familial Hypercholesterolaemia in Children and Adolescents: Current and Future Perspectives

Author(s): Francesco Martino, Francesco Barilla, Eliana Martino, Giuseppe Calcaterra, Vassilios Fanos and Pier Paolo Bassareo*

Volume 19, Issue 3, 2023

Published on: 11 November, 2022

Page: [234 - 241] Pages: 8

DOI: 10.2174/1573396318666220921155314

Price: $65

Abstract

Familial hypercholesterolemia (FH) is a genetic disease, the underlying cause of which is represented by mutations capable of influencing the metabolism of low-density lipoproteins (LDL). The distinguishing characteristic of FH has increased LDL cholesterol blood levels since birth, triggering early development of atherosclerosis-related diseases. Diagnosis of FH is frequently either missed or made with a considerable delay. Prompt identification of the disease is pivotal in implementing early prevention measures. Safe and effective drugs have been approved for use in children and adolescents, with statins, with or without ezetimibe, representing first-line therapy. At times, however, these medications may not be sufficient to achieve the therapeutic target, particularly in homozygous FH patients. Lipoprotein apheresis, which has proved safe and efficient, is strongly suggested in such cases. New drugs still at the investigational stage may represent a promising and personalised therapy. Lowering cholesterol levels in childhood hampers the formation of arterial atherosclerotic plaques, thus reducing cardiovascular events later in life. Accordingly, early detection, diagnosis, and therapy in FH subjects are priority aims.

Keywords: familial hypercholesterolemia, low-density lipoprotein cholesterol, statin, ezetimibe. proprotein convertase subtilisin/kexin type 9, lipoprotein apheresis

« Previous Next »
Graphical Abstract

[1]
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart,Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Sum-mary report. Pediatrics 2011; 128(S5): S213-56.
[http://dx.doi.org/10.1542/peds.2009-2107C]
[2]
Françoso LA, Coates V. Anatomicopathological evidence of the beginning of atherosclerosis in infancy and adolescence. Arq Bras Cardiol 2002; 78(1): 131-42.
[http://dx.doi.org/10.1590/S0066-782X2002000100014]
[3]
Juonala M, Viikari JSA, Kähönen M, et al. Life-time risk factors and progression of carotid atherosclerosis in young adults: The Cardio-vascular Risk in Young Finns study. Eur Heart J 2010; 31(14): 1745-51.
[http://dx.doi.org/10.1093/eurheartj/ehq141] [PMID: 20501481]
[4]
Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The bogalusa heart study. N Engl J Med 1998; 338(23): 1650-6.
[http://dx.doi.org/10.1056/NEJM199806043382302] [PMID: 9614255]
[5]
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries: Case-control study. Lancet 2004; 364(9438): 937-52.
[http://dx.doi.org/10.1016/S0140-6736(04)17018-9] [PMID: 15364185]
[6]
Landmesser U, Hornig B, Drexler H. Endothelial function. Circulation 2004; 109(21) (Suppl. 1): II27-33.
[http://dx.doi.org/10.1161/01.CIR.0000129501.88485.1f] [PMID: 15173060]
[7]
Martino F, Loffredo L, Carnevale R, et al. Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: The potential role of nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics 2008; 122(3): e648-55.
[http://dx.doi.org/10.1542/peds.2008-0735] [PMID: 18762499]
[8]
Loffredo L, Martino F, Carnevale R, et al. Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. J Pediatr 2012; 161(6): 1004-9.
[http://dx.doi.org/10.1016/j.jpeds.2012.05.042] [PMID: 22727869]
[9]
Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, Stefanadis C. Arterial endothelial function and wall thickness in fa-milial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis 2011; 214(1): 129-38.
[http://dx.doi.org/10.1016/j.atherosclerosis.2010.10.008] [PMID: 21074770]
[10]
Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008; 28(4): 777-85.
[http://dx.doi.org/10.1161/ATVBAHA.107.160408] [PMID: 18239150]
[11]
Fahed AC, Shibbani K, Andary RR, et al. Premature valvular heart disease in homozygous familial hypercholesterolemia. Cholesterol 2017; 2017: 1-7.
[http://dx.doi.org/10.1155/2017/3685265] [PMID: 28761763]
[12]
Narverud I, Retterstøl K, Iversen PO, et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: A liter-ature review. Atherosclerosis 2014; 235(2): 299-309.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.917] [PMID: 24908240]
[13]
Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The framing-ham study. Ann Intern Med 1971; 74(1): 1-12.
[http://dx.doi.org/10.7326/0003-4819-74-1-1] [PMID: 5539274]
[14]
Friedman M. Pathogenesis of the spontaneous atherosclerotic plaque. A study on the cholesterol-fed rabbit. Arch Pathol 1963; 76: 318-29.
[PMID: 14058158]
[15]
Tada H, Usui S, Sakata K, Takamura M, Kawashiri M. Low-density lipoprotein cholesterol level cannot be too low: Considerations from clinical trials, human genetics, and biology. J Atheroscler Thromb 2020; 27(6): 489-98.
[http://dx.doi.org/10.5551/jat.RV17040] [PMID: 32350167]
[16]
Rizvi AA, Montalto G, Patti AM, Rizzo M. Oxidative stress and small, dense low-density lipoproteins: Current and future perspectives. Expert Rev Endocrinol Metab 2012; 7(4): 415-7.
[http://dx.doi.org/10.1586/eem.12.30] [PMID: 30754159]
[17]
Rizzo M, Corrado E, Coppola G, Muratori I, Novo G, Novo S. Prediction of cardio- and cerebro-vascular events in patients with subclini-cal carotid atherosclerosis and low HDL-cholesterol. Atherosclerosis 2008; 200(2): 389-95.
[http://dx.doi.org/10.1016/j.atherosclerosis.2007.12.020] [PMID: 18258237]
[18]
Linton MF, Yancey PG, Davies SS, et al. The role of lipids and lipoproteins in atherosclerosisEndotext South Dartmouth (MA): MDTextcom, Inc 2000.
[19]
de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the american heart association. Circulation 2019; 139(13): e603-34.
[http://dx.doi.org/10.1161/CIR.0000000000000618] [PMID: 30798614]
[20]
Garrido-Miguel M, Cavero-Redondo I, Álvarez-Bueno C, et al. Prevalence and trends of overweight and obesity in european children from 1999 to 2016. JAMA Pediatr 2019; 173(10): e192430.
[http://dx.doi.org/10.1001/jamapediatrics.2019.2430] [PMID: 31381031]
[21]
Newman WP III, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa heart study. N Engl J Med 1986; 314(3): 138-44.
[http://dx.doi.org/10.1056/NEJM198601163140302] [PMID: 3455748]
[22]
Lauer RM, Clarke WR. Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia. The muscatine study. JAMA 1990; 264(23): 3034-8.
[http://dx.doi.org/10.1001/jama.1990.03450230070031] [PMID: 2243431]
[23]
Juonala M, Viikari JSA, Rönnemaa T, et al. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thick-ness, elasticity, and brachial flow-mediated dilatation in adulthood: the cardiovascular risk in young finns study. Arterioscler Thromb Vasc Biol 2008; 28(5): 1012-7.
[http://dx.doi.org/10.1161/ATVBAHA.108.163329] [PMID: 18309111]
[24]
Gidding SS, McMahan CA, McGill HC, et al. Prediction of coronary artery calcium in young adults using the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) risk score: The CARDIA study. Arch Intern Med 2006; 166(21): 2341-7.
[http://dx.doi.org/10.1001/archinte.166.21.2341] [PMID: 17130387]
[25]
Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: Knowledge base, limitations, and future directions. Pediatrics 2007; 119(2): 370-80.
[http://dx.doi.org/10.1542/peds.2006-0787] [PMID: 17272627]
[26]
Martino F, Pignatelli P, Martino E, et al. Early increase of oxidative stress and soluble CD40L in children with hypercholesterolemia. J Am Coll Cardiol 2007; 49(19): 1974-81.
[http://dx.doi.org/10.1016/j.jacc.2007.01.082] [PMID: 17498583]
[27]
Mosca S, Araújo G, Costa V, et al. Dyslipidemia diagnosis and treatment: Risk stratification in children and adolescents. J Nutr Metab 2022; 2022: 1-10.
[http://dx.doi.org/10.1155/2022/4782344] [PMID: 35237450]
[28]
Pignatelli P, Loffredo L, Martino F, et al. Myeloperoxidase overexpression in children with hypercholesterolemia. Atherosclerosis 2009; 205(1): 239-43.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.10.025] [PMID: 19081093]
[29]
Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol 2019; 16(1): 9-20.
[http://dx.doi.org/10.1038/s41569-018-0052-6] [PMID: 29973710]
[30]
Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: New insights in pathogenesis and treatment. J Clin Invest 2003; 111(12): 1795-803.
[http://dx.doi.org/10.1172/JCI200318925] [PMID: 12813012]
[31]
Hu H, Cheng J, Lin S, Wang S, Chen X. Calcified aortic valve disease in patients with familial hypercholesterolemia. J Cardiovasc Pharmacol 2020; 76(5): 506-13.
[http://dx.doi.org/10.1097/FJC.0000000000000890] [PMID: 33165132]
[32]
Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009; 29(4): 431-8.
[http://dx.doi.org/10.1161/ATVBAHA.108.179564] [PMID: 19299327]
[33]
Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers 2017; 3(1): 17093.
[http://dx.doi.org/10.1038/nrdp.2017.93] [PMID: 29219151]
[34]
Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, ge-netic, and therapeutic insights: A consensus statement from the european atherosclerosis society consensus panel. Eur Heart J 2020; 41(24): 2313-30.
[http://dx.doi.org/10.1093/eurheartj/ehz962] [PMID: 32052833]
[35]
Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: Screening of 98 098 individuals from the copenhagen general population study estimated a prevalence of 1 in 217. Eur Heart J 2016; 37(17): 1384-94.
[http://dx.doi.org/10.1093/eurheartj/ehw028] [PMID: 26908947]
[36]
Fellin R, Arca M, Zuliani G, Calandra S, Bertolini S. The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification. Gene 2015; 555(1): 23-32.
[http://dx.doi.org/10.1016/j.gene.2014.09.020] [PMID: 25225128]
[37]
Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52(7): 1544-68.
[http://dx.doi.org/10.1172/JCI107332] [PMID: 4718953]
[38]
Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia. J Am Coll Cardiol 2020; 75(20): 2553-66.
[http://dx.doi.org/10.1016/j.jacc.2020.03.057] [PMID: 32439005]
[39]
Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, et al. Global perspective of familial hypercholesterolaemia: A cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 2021; 398(10312): 1713-25.
[http://dx.doi.org/10.1016/S0140-6736(21)01122-3] [PMID: 34506743]
[40]
Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimiz-ing detection and treatment. Eur Heart J 2015; 36(36): 2425-37.
[http://dx.doi.org/10.1093/eurheartj/ehv157] [PMID: 26009596]
[41]
Vallejo-Vaz AJ, De Marco M, Stevens CAT, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 coun-tries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis 2018; 277: 234-55.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.08.051]
[42]
Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl 2016; 22: 1-32.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2016.10.001]
[43]
Hajighasemi S, Mahdavi GA, Bianconi V, et al. A review of gene- and cell-based therapies for familial hypercholesterolemia. Pharmacol Res 2019; 143: 119-32.
[http://dx.doi.org/10.1016/j.phrs.2019.03.016] [PMID: 30910740]
[44]
Di Taranto MD, Giacobbe C, Fortunato G. Familial hypercholesterolemia: A complex genetic disease with variable phenotypes. Eur J Med Genet 2020; 63(4): 103831.
[http://dx.doi.org/10.1016/j.ejmg.2019.103831] [PMID: 31883481]
[45]
Bianconi V, Banach M, Pirro M. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. Trends Cardiovasc Med 2021; 31(4): 205-15.
[http://dx.doi.org/10.1016/j.tcm.2020.03.004] [PMID: 32205033]
[46]
Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the european atherosclerosis society. Eur Heart J 2013; 34(45): 3478-90.
[http://dx.doi.org/10.1093/eurheartj/eht273] [PMID: 23956253]
[47]
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37(29): 2315-81.
[http://dx.doi.org/10.1093/eurheartj/ehw106] [PMID: 27222591]
[48]
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PC NA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/ American Heart Association task force on clinical practice guidelines. S Circulation 2019; 139(25): e1046-81.
[http://dx.doi.org/10.1161/CIR.0000000000000624] [PMID: 30565953]
[49]
Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemias: Recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 2011; 5(3) (Suppl.): S30-7.
[http://dx.doi.org/10.1016/j.jacl.2011.03.453] [PMID: 21600527]
[50]
Winchester B, Cragun D, Redlinger-Grosse K, et al. Application of motivational interviewing strategies with the extended parallel process model to improve risk communication for parents of children with familial hypercholesterolemia. J Genet Couns 2022; 31(4): 847-59.
[http://dx.doi.org/10.1002/jgc4.1554] [PMID: 35150174]
[51]
Singh S, Bittner V. Familial hypercholesterolemia--epidemiology, diagnosis, and screening. Curr Atheroscler Rep 2015; 17(2): 3.
[http://dx.doi.org/10.1007/s11883-014-0482-5] [PMID: 25612857]
[52]
Singh A, Gupta A, Collins BL, et al. Familial hypercholesterolemia among young adults with myocardial infarction. J Am Coll Cardiol 2019; 73(19): 2439-50.
[http://dx.doi.org/10.1016/j.jacc.2019.02.059] [PMID: 31097165]
[53]
Hauguel-Moreau M, Aïdan V, Hergault H, et al. Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. Arch Cardiovasc Dis 2022; 115(2): 87-95.
[http://dx.doi.org/10.1016/j.acvd.2021.11.005] [PMID: 35123917]
[54]
Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: Prevalence, genetics, diagnosis and screening recom-mendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 2011; 5(S3): S9-S17.
[http://dx.doi.org/10.1016/j.jacl.2011.03.452] [PMID: 21600530]
[55]
Pang J, Martin AC, Mori TA, Beilin LJ, Watts GF. Prevalence of familial hypercholesterolemia in adolescents: Potential value of universal screening? J Pediatr 2016; 170: 315-6.
[http://dx.doi.org/10.1016/j.jpeds.2015.11.019] [PMID: 26690851]
[56]
Avis HJ, Kusters DM, Vissers MN, et al. Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screen-ing program. J Pediatr 2012; 161(1): 99-103.
[http://dx.doi.org/10.1016/j.jpeds.2011.12.037] [PMID: 22284919]
[57]
Ned RM, Sijbrands EJ. Cascade screening for Familial Hypercholesterolemia (FH). PLoS Curr 2011; 3: RRN1238.
[58]
O’Brien EC, Roe MT, Fraulo ES, et al. Rationale and design of the familial hypercholesterolemia foundation cascade screening for aware-ness and detection of familial hypercholesterolemia registry. Am Heart J 2014; 167(3): 342-349.e17.
[http://dx.doi.org/10.1016/j.ahj.2013.12.008] [PMID: 24576518]
[59]
Bell DA, Pang J, Burrows S, et al. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis 2015; 239(1): 93-100.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.12.036] [PMID: 25585028]
[60]
Minicocci I, Pozzessere S, Prisco C, et al. Analysis of children and adolescents with familial hypercholesterolemia. J Pediatr 2017; 183: 100-107.e3.
[http://dx.doi.org/10.1016/j.jpeds.2016.12.075] [PMID: 28161202]
[61]
Montali A, Truglio G, Martino F, et al. Atherogenic dyslipidemia in children: Evaluation of clinical, biochemical and genetic aspects. PLoS One 2015; 10(4): e0120099.
[http://dx.doi.org/10.1371/journal.pone.0120099] [PMID: 25897955]
[62]
Vuorio AF, Miettinen TA, Turtola H, Oksanen H, Gylling H. Cholesterol metabolism in normal and heterozygous familial hypercholester-olemic newborns. J Lab Clin Med 2002; 140(1): 35-42.
[http://dx.doi.org/10.1067/mlc.2002.125214] [PMID: 12080326]
[63]
Parums DV. Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Car-diovascular Disease (ASCVD). Med Sci Monit 2021; 27: e935172.
[http://dx.doi.org/10.12659/MSM.935172] [PMID: 34690345]
[64]
Marks D, Thorogood M, Neil HAW, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholester-olaemia. Atherosclerosis 2003; 168(1): 1-14.
[http://dx.doi.org/10.1016/S0021-9150(02)00330-1] [PMID: 12732381]
[65]
Ramaswami U, Futema M, Bogsrud MP, et al. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis 2020; 292: 178-87.
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.11.012] [PMID: 31809987]
[66]
Bertolini S, Calandra S, Arca M, et al. Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features. Atherosclerosis 2020; 312: 72-8.
[http://dx.doi.org/10.1016/j.atherosclerosis.2020.08.027] [PMID: 32977124]
[67]
Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and mon-ogenic familial hypercholesterolaemia: A case-control study. Lancet 2013; 381(9874): 1293-301.
[http://dx.doi.org/10.1016/S0140-6736(12)62127-8] [PMID: 23433573]
[68]
Campagna F, Martino F, Bifolco M, et al. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: Results of a family and DNA-based screening. Atherosclerosis 2008; 196(1): 356-64.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.11.015] [PMID: 17196209]
[69]
Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia. J Am Coll Cardiol 2018; 72(6): 662-80.
[http://dx.doi.org/10.1016/j.jacc.2018.05.044] [PMID: 30071997]
[70]
Molven I, Retterstøl K, Andersen LF, et al. Children and young adults with familial hypercholesterolaemia (FH) have healthier food choic-es particularly with respect to dietary fat sources compared with non-FH children. J Nutr Sci 2013; 2: e32.
[http://dx.doi.org/10.1017/jns.2013.27] [PMID: 25191582]
[71]
Cicero AFG, Colletti A, Bajraktari G, et al. Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. Nutr Rev 2017; 75(9): 731-67.
[http://dx.doi.org/10.1093/nutrit/nux047] [PMID: 28938795]
[72]
Steinberg D. The rationale for initiating treatment of hypercholesterolemia in young adulthood. Curr Atheroscler Rep 2013; 15(1): 296.
[http://dx.doi.org/10.1007/s11883-012-0296-2] [PMID: 23232986]
[73]
Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: A meta-analysis of randomised controlled studies. Br J Nutr 2014; 112(2): 214-9.
[http://dx.doi.org/10.1017/S0007114514000750] [PMID: 24780090]
[74]
Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232(2): 346-60.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.11.043] [PMID: 24468148]
[75]
Martino F, Martino E, Morrone F, Carnevali E, Forcone R, Niglio T. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis 2005; 15(3): 174-80.
[http://dx.doi.org/10.1016/j.numecd.2004.04.004] [PMID: 15955465]
[76]
Martino F, Puddu PE, Pannarale G, et al. Low dose chromium-polynicotinate or policosanol is effective in hypercholesterolemic children only in combination with glucomannan. Atherosclerosis 2013; 228(1): 198-202.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.02.005] [PMID: 23453352]
[77]
Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F. The treatment of hypercholesterolemic children: Efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 2011; 21(6): 424-9.
[http://dx.doi.org/10.1016/j.numecd.2009.10.015] [PMID: 20153154]
[78]
Manousaki D, Barnett TA, Mathieu ME, et al. Tune out and turn in: The influence of television viewing and sleep on lipid profiles in chil-dren. Int J Obes 2020; 44(5): 1173-84.
[http://dx.doi.org/10.1038/s41366-020-0527-5] [PMID: 32203106]
[79]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[80]
Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019; 381(16): 1547-56.
[http://dx.doi.org/10.1056/NEJMoa1816454] [PMID: 31618540]
[81]
Dombalis S, Nash A. The effect of statins in children and adolescents with familial hypercholesterolemia: A systematic review. J Pediatr Health Care 2021; 35(3): 292-303.
[http://dx.doi.org/10.1016/j.pedhc.2020.11.007] [PMID: 33342622]
[82]
Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: A systematic review and meta-analysis of randomized-controlled trials. Endocrine 2020; 69(2): 249-61.
[http://dx.doi.org/10.1007/s12020-020-02302-8] [PMID: 32333266]
[83]
van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008; 52(17): 1421-9.
[http://dx.doi.org/10.1016/j.jacc.2008.09.002] [PMID: 18940534]
[84]
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Atherosclerosis 2016; 253: 281-344.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.08.018]
[85]
Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med 2020; 383(14): 1317-27.
[http://dx.doi.org/10.1056/NEJMoa2019910] [PMID: 32865373]
[86]
van Bergen EHK, Hutten BA, Luirink IK, Wiegman A, de Groot E, Kusters DM. .Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis. J Clin Lipidol 2022; S1933-2874(22): 25-33.
[http://dx.doi.org/10.1016/j.jacl.2022.01.009]
[87]
Luirink IK, Hutten BA, Greber-Platzer S, et al. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry. Atherosclerosis 2020; 299: 24-31.
[http://dx.doi.org/10.1016/j.atherosclerosis.2020.01.031] [PMID: 32199148]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy